Eli Lilly Receives FDA Approval For Olumiant In Pediatric Patients Aged 12 And Older With Severe Alopecia Areata
FDA approval supported by data from BRAVE-AA-PEDS, the first and largest Phase 3 study specifically designed to evaluate pediatric patients with severe alopecia areata (AA)Treatment with Olumiant resulted in
Eli Lilly got approval to treat hair loss in kids aged 12 and older. This shows the medicine works for young people, which opens a new customer group.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.